跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BEYFORTUS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BEYFORTUS
Authorized
STANDARD
BEYFORTUS
Sanofi Pasteur Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
6909f0dfa0d61517
Company
Sanofi Pasteur Limited
Type
Standard
Approval Details
Approval Id
6909f0dfa0d61517
Drug Approval Canada Name
BEYFORTUS
Product Name
BEYFORTUS
Status
Marketed
Status Date
2024-11-04
Original Market Date
2024-11-04
Din
02537214
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
08:18.24
Atc Original
J06BD08 NIRSEVIMAB
Atc Name
j 06 bd 08
Aig Number
0164561001
Company Name
Sanofi Pasteur Limited
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Company Detail Path
/organization/sanofi-pasteur-limited
Company Information
Pharmaceutical Company Name
Sanofi Pasteur Limited
Country Name
Canada
Province Name
Ontario
City Name
north york,ontario,country_ca
Address
1755 Steeles Ave W
Active Ingredients
NIRSEVIMAB
100 MG / 1 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
6909f0dfa0d61517
Type
Standard
Back to Health Canada Approvals